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INTRODUCTION
Melanotic neuroectodermal tumour of infancy (MNTI)
was first described by Krompecher in 1918. However, it
was named several years later in 1966, by Borello and
Gorlin, after they reported a case with elevated urinary
levels of VMA suggesting a neural crest origin.1,2
Melanotic neuroectodermal tumour of infancy (MNTI) is
a rare, osteolytic pigmented lesion of neural crest origin,
occurring in infants.3 Majority of cases have been
reported in the maxilla, with the skull and the brain being
less common locations. Very rarely MNTI can also be
found in the epididymis, mediastinum and the female
reproductive organs.2 Although melanotic neuroecto-
dermal tumour of infancy is mostly benign, a malignancy
rate of 6.6% has been reported.2 The majority of cases
occur within the first year of life without any gender
predilection.1,2,4,5
MNTI often presents as a swiftly growing mass resulting
in skull deformation.4 The recurrence rates after resec-
tions have been reported from 10% to as high as 60%.2,5
Here, we present the first case of MNTI from Pakistan.
CASE REPORT
An 8 months old female presented with a swelling on the
scalp for the last 6 months. The swelling appeared
gradually and was progressive. There was no history of
trauma, fever, weight loss, vomiting or seizures. She had
otherwise normal growth and development milestones.
On examination, the lesion was a 5 x 6 cm midline
swelling which was non-tender and firm. The overlying
skin was mobile but the lesion was attached to the
underlying structures. The lesion was located in the
anterior parasagittal skull with dural involvement. A CT
scan was carried out which showed an iso- to hypo-
dense lesion with reactionary bony enlargement,
compressing the superior sagittal sinus (Figure 1). An
excision biopsy was performed which showed a right
frontal lesion that was firm in consistency, grayish in
colour and avascular. There was involvement of the
subgaleal tissue, pericranium, bone and dura mater. The
lesion was removed enbloc along with involved dura
mater. There was no brain parenchymal involvement.
Duraplasty was performed using normal pericranium
and a cranioplasty was carried out using bone cement.
Histopathology reports finally confirmed it to be a
melanotic neuroectodermal tumour of infancy. Sections
examined showed a lesion composed of variable sized
tubule-like structures and nests of small cells. Tubule-
like structures were composed of flattened to polygonal
melanin pigment containing cells. Nuclei were small and
exhibit evenly dispersed chromatin pattern. Within the
luminal spaces, small euplastic cell aggregates were
seen with a central fibrillary background imparting a
rosette like architecture. These tubules and nests of
cells were scattered in a fibrous stroma with variable
sized blood vessels. In some areas, loosely arranged
small neoplastic cells with a fibrillary background were
seen in the fibrotic stroma (Figure 2 and 3).
On follow-up at 3 months, the child was asymptomatic,
her urinary VMA levels were within normal limits and she
had fully recovered. The child was followed-up for 2
years and there was no recurrence of tumour or clinical
symptoms.
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ABSTRACT
Melanotic neuroectodermal tumour of infancy is a rare, mostly benign but locally aggressive tumour of neural crest cell
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DISCUSSION
Most MNTI lesions occur in the maxilla, with skull and
brain involvement being quite rare (Figure 4).2 Primary
tumours originating from the brain itself are even rarer
and very few cases have been reported involving the
cerebellar vermis and the third ventricle.6
Signs of anaplasia such as mitoses and pleomorphism
are not evident in MNTI. Under a light microscope, three
different kinds of cells can be appreciated. The first
resemble epithelial cells are large with abundant
cytoplasm, have many vacuoles and a large ovoid
sharply marginated nucleus. The second cell type has a
hyper chromatic nucleus with a non-pigmented cyto-
plasm and is small and immature while the third type of
cells are small, stellate and resemble fibroblasts.4 The
tumour cells are divided into clusters with slit like alveoli
which are irregular in size and shape.4
The lesion may be mistaken as malignant due to its
rapid growth rate, therefore, careful workup especially
that of histopathology is advocated before a final
diagnosis is reached. Various studies show that the
MNTI is a congenital dysembryogenetic neoplasm
arising out of neural crest cells.1 Like other tumours of
neural crest origin, MNTI secretes VMA and other
catecholamines, the levels of which go down after
complete tumour excision.7 MNTI also expresses melano-
transferrin which further supports its neuroectodermal
origin.1
However, VMA is not diagnostic as many patients have
also shown normal urinary VMA levels.8 This is probably
because not all the cells of neural crest origin are
involved in the metabolism of cathecolamines.8
Immunocytochemistry is also of help. The smaller hyper
chromatic neuroblast-like cells are usually positive for
neuron-specific enolase, glial fibrillary acidic protein, and
synaptophysin; while the larger epithelioid cells may be
positive for vimentin, cytokeratin, epithelial membrane
antigen, neuron-specific enolase, glial fibrillary acidic
protein, synaptophysin, Leu 7, and HMB45.1 S-100
protein, alpha fetoprotein and nerofilament are usually
non-reactive.1 This can help differentiate MNTI from
other PNETs (Primitive Neuro Ectodermal Tumours).
Neoplastic cells with poly-phenotypic expression of
neural, melanocytic and neural markers exhibit no
photo-receptor or myogenic differentiation.1
Clinical differentials are broad but MNTI must be
distinguished from Ewing's sarcoma, rhabdomyo-
sarcoma, peripheral neuroepithelioma, neuroblastoma,
desmoplastic round cell tumour, leukemia, malignant
melanoma, and infections or cephalohematomas.1,2,9
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Figure 1: A,B,C: Pre-operative CT scans of the patient showing an iso to
hypo dense lesion with reactionary bony enlargement, and which was
compressing the superior sagittal sinus. D,E,F: Postoperative contrast
enhanced T1 images showing complete tumour excision without recurrence.
Figure 2: Low power view (2X); Alveolar nests and tubules of cells separated
by fibrous stroma.
Figure 3: Low power view (4X) Tubules are populated by two cell types: a
peripheral layer of melanin-pigmented large cells surrounding groups of
small neuroblastic type cells.
Figure 4: Distribution of reported cranial MNTI from 1977 to 2008. Total
number (n = 43).
MNTI can be differentiated from Ewing's sarcoma,
peripheral neuroepithelioma, desmoplastic round cell
tumour, leukemia and infections or cephalohematomas
as it has biphasic neoplastic population and a
polyphenotypic immunohistochemical expression.7
The lack of S-100 reactivity coupled with lack of
neuroendocrine differentiation markers, myo D-1,
myoglobin, myogenin and muscle specific Actin reacti-
vity can differentiate MNTI from cellular blue nevus,
melanoma, neuroblastoma and rhabdomyosarcoma.1
In the course of the disease, a well demarcated
osteolytic radiolucency is found which may have regular
or irregular borders. A well grown MNTI can cause
displacement of the surrounding tissues and damage
the bone as well.6 However, these changes may not be
apparent if the conventional radiographs are done early.
MR angiography can prove particularly useful in midline
tumours that have invaded the dural sinuses as it can
best demonstrate the adherence of tumour to the
sinuses.2,4 The boundaries of the tumour are well
demarcated on CT scan and serve as good guides for
surgical excision.2 The tumour appears hyper to iso
intense on T1 weighted images and exhibits homo-
genous enhancement after a gadolinium contrast, while
on T2 weighted images it appears hypo intense.6
However, the peripheral margins of the tumour in direct
apposition to bone may appear hypo intense on T1
weighted images.6 A pre-operative cytological diagnosis
of MNTI through aspirates from the site of the lesion is
possible.4
The MNTI is a locally aggressive tumour. After a
complete surgical resection, the chances of recurrence
are reported between 10% to 20%.5 The probability of
the tumour becoming malignant is 6.5%.5 Most
recurrences after complete resection occur with 4
weeks; there was one exception where the tumour
recurred after being in remission for 12 years.5
Incomplete surgical resections have recurrence rates as
high as 60%.2,5,10 At present, there is no effective
adjuvant therapy for recurrent and residual tumour.3 A
complete surgical resection wherever possible, offers a
definitive cure for the vast majority of the patients.
Surgical outcomes are better if the tumour is in a
favourable location. Tumours along the midline or cranial
base and those adherent to dural sinuses or tumours
with significant intracranial extensions are difficult to
manipulate surgically and a complete excision may not
be possible.4 Furthermore, the use of operating
microscope ensures the complete resection of tumour
when it is in a favourable location; missed parts of the
tumour may cause recurrence. Complete enbloc
excision reduces the anaesthetic risks and undue
manipulation of the lesion which occurs during a prior
biopsy. It has been reported that the tumour grows more
aggressively along the site of a previous biopsy.1
Recurrence may also occur because of inadvertent
seeding during the excision surgery. 
It is also noteworthy that the biological behaviour of the
MNTI, such as local growth rate and the possibility of
metastasis cannot be judged adequately from either
clinical or histological features.5 Patient's family should
be informed of all these variables in treatment. The child
should be followed-up till adulthood so that surgical
complications and recurrences can be picked up early
and managed accordingly allowing the child to reach
normal growth and development milestones.
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